Hedge fund Bluebell also demands replacement of GlaxoSmithKline chairman Sir Jonathan Symonds
The British drugmaker GlaxoSmithKline has come under fresh pressure to sell off its consumer arm and carry out a change of leadership, with a hedge fund demanding the appointment of a new chairman.
Bluebell Capital Partners, an activist London-based hedge fund that has taken a small stake in GSK, has written to the company to demand that Sir Jonathan Symonds be replaced as chairman.
